You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window
Free

Authors

Citation

Chen S, Dominik P, Stanfield J, et al
267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window
Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.267

Publication history

  • First published November 10, 2021.
Online issue publication 
March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.